ABSTRACT
Delivering inhaled drugs to neonatal and pediatric populations has unique challenges. Knowledge acquired on adults is not transferable to neonatal-pediatric patients, who have significant anatomical, physiological, and behavioral differences compared to adults. Thus, neonatal-pediatric patients have particular problems when operating or receiving aerosolized drugs from different delivery devices. Aerosols are delivered to neonatal-pediatric patients while receiving respiratory support with heated high-flow nasal cannula, and noninvasive and invasive ventilation. The latter occurs through different artificial airways (tracheostomy and endotracheal tubes). Drugs and devices are not typically designed for their use in neonatal-pediatric patients. Chapter 8 addresses these topics and discusses the currently available data (human and animal in vivo, in vitro, and in silico).
